Fabrication of composite microparticles of artemisinin for dissolution enhancement

Powder Technology

Volumn 203, Issue 2, 2010, Pages 277-287

  Sahoo, Nanda Gopal ^a   Kakran, Mitali ^a   Li, Lin ^a   Judeh, Zaher ^b  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b Nanyang Technological University   (Singapore)

Author keywords

Artemisinin; Crystallinity; Dissolution; Microparticles; Spray drying

Indexed keywords

ANTIMALARIAL DRUG; ARTEMISININ; BEST FIT; COMMON SOLVENTS; COMPOSITE MICROPARTICLES; CRYSTALLINITIES; CRYSTALLINITY; DISSOLUTION ABILITY; DISSOLUTION TIME; DRUG RELEASE KINETICS; FEED RATIOS; FICKIAN DIFFUSION; FOURIER TRANSFORM INFRARED; HYDROPHILIC POLYMERS; IN-VITRO DISSOLUTION; MATHEMATICAL MODELING; MICRO-PARTICLES; MULTI-FLUIDS; PEPPAS MODEL; PHYSICAL MIXTURES; POLYMER COMPOSITE; POLYVINYL PYRROLIDONE; POORLY WATER-SOLUBLE DRUGS; SEM; SIMILARITY FACTORS; STATISTICAL ANALYSIS; WATERSOLUBLE; WEIBULL; WEIGHT RATIOS; XRD STUDIES;

CURING; DIFFERENTIAL SCANNING CALORIMETRY; FLUIDS; FOURIER TRANSFORMS; HYDROPHILICITY; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYVINYL ALCOHOLS; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SPRAY NOZZLES; WAVELET TRANSFORMS; X RAY DIFFRACTION;

DISSOLUTION;

ARTEMISIN; MACROGOL;

ARTICLE; COMPOSITE MATERIAL; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG MIXTURE; DRUG RELEASE; DRUG SOLUBILITY; EQUIPMENT DESIGN; IN VITRO STUDY; INFRARED SPECTROSCOPY; MATHEMATICAL MODEL; MICROTECHNOLOGY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; POWDER; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; X RAY DIFFRACTION;

EID: 77955514171     PISSN: 00325910     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.powtec.2010.05.019     Document Type: Article

References (34)

1. Lipinsk C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
2. Subramaniam B., Rajewski R.A., Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J. Pharm. Sci. 1997, 86:885-890.
3. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86:1-12.
4. Grau M.J., Kayser O., Muller R.H. Nanosuspensions of poorly soluble drugs-reproducibility of small scale production. Int. J. Pharm. 2000, 196:155-157.
5. Merisko-Liverside E., Liversidge G.G., Cooper E.R. Nonosizing: a formulation approach for poorly-water soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
6. Rasenack N., Hartenhauer H., Muller B.W. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm. 2003, 254:137-145.
7. Rogers T.L., Overhoff K.A., Shah P., Santiago P., Yacaman M.J., Johnson K.P., William R.O. Micronized powders of a poorly water soluble drug produced by a spray-feezing into liquid-emulsion process. Eur. J. Pharm. Biopharm. 2003, 55:161-172.
8. Takeuchi H., Nagira S., Yamamoto H., Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int. J. Pharm. 2005, 293:155-164.
9. Moretti M.D.L., Gavini E., Juliano C., Pirisino G., Giunchedi P. spray dried microspheres coantaining ketoprofen formulated into capsules and tablets. J. Microencapsul. 2001, 18:111-121.
10. Jung J., Perrut M. Particle design using supercritical fluids: literature and patent survey. J. Super. Fluids. 2001, 20:179-219.
11. Augustijns P., D'Hulst A., Daele J.V., Kinget R. Transport of artemisinin and sodium arsenate in caco-2 intestinal epithelial cells. J. Pharm. Sci. 1996, 85:577-579.
12. Barradell L.B., Fitton A. Artesunate, a review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs 1995, 50:714-741.
13. Titulaer H.A.C., Zuidema J., Lugt C.B. Formulation and pharmacokinetics of arthemisinin and its derivatives. Int. J. Pharm. 1991, 69:83-92.
14. Wong J.W., Yuen K.H. Improved oral bioavailability of artemisinin through inclusion complexation with β-, and γ-cyclodextrins. Int. J. Pharm. 2001, 227:177-185.
15. Wong J.W., Yuen K.H. Inclusion complexation of artemisinin with α-, β-, and γ-cyclodextrins. Drug Dev. Ind. Pharm. 2003, 29:1035-1044.
16. Beppu B., Ozeki T., Sasaki Y., Mizoe T., Takashima Y., Yuasa H., Okada H. Preparation of particles for dry powder inhalation using a novel 4-fluid nozzle spray drier. J. Pharm. Sci. Technol., Jpn. 2003, 63:228-237.
17. Sahoo N.G., Abbas A., Judeh Z., Li C.M., Yuen K.H. Solubility enhancement of a poorly water-soluble anri-malarial drug: experimental design and use of a modified multifluid nozzle pilot spray drier. J. Pharm. Sci. 2009, 98:281-296.
18. Zhao S.S. High-performance liquid chromatographic determination of artemisinin (qinghaosu) in human plasma and saliva. Analyst 1987, 112:661-664.
19. Higuchi T., Connors K. Phase solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4:17-123.
20. Martin A. Physical Pharmacy, Physical Chemical Principles in the Pharmaceutical Sciences 1993, Lea and Febiger, Philadelphia. 4th ed.
21. Ahuja N., Katare O.M., Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eup. J. Pharm. Biopharm. 2007, 65:26-38.
22. Costa P., Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13:123-133.
23. Ozeki T., Beppu S., Mizoe T., Takashima Y., Yuasa H., Okada H. Preparation of two-drug composite microparticles to improve the dissolution of insoluble drug in water for use with a 4-fluid nozzle spray drier. J. Control. Release 2005, 107:387-394.
24. Cirri M., Mura P., Rabasco A.M., Ginés J.M., Moyano J.R., Gònzalez-Rodrìguez M.L. Characterization of ibuproxam binary and ternary dispersions with hydrophilic carriers. Drug Dev. Ind. Pharm. 2004, 30:65-74.
25. Shahjahan M., Enever R.P. Investigation of the nature of the interaction of nitrofurazone with urea. Int. J. Pharm. 1992, 82:229-232.
26. Jain A.C., Adeyeye M.C. Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether-β-cyclodextrins (SBE) and danazol-SBE inclusion complexes. Int. J. Pharm. 2001, 212:177-186.
27. Reppas C., Nicolaides E. Oral Drug Absorption Prediction and Assessment 2000, 229-254. Marcel Dekker, Inc, New York. J.B. Dressman, H. Lennernäs (Eds.).
28. Vueba M.L., Batista de Carvalho L.A.E., Veiga F., Sousa J.J., Pina M.E. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets. Eur. J. Pharm. Biopharm. 2004, 58:51-59.
29. Demirtürk E., Öner L. Evaluation of in vitro dissolution profile comparison methods of immediate release gliclazide tablet formulations. J. Facul. Pharm. 2005, 25:1-10.
30. Noyes A.A., Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19:930-934.
31. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev. 2001, 47:3-19.
32. Hancock B.C., Zografi G. Characteristic and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86:1-12.
33. ® E100. Drug Dev. Ind. Pharm. 2004, 30:303-317.
34. Korsmeyer R.W., Gurney R., Doelker E., Buri P., Peppas N.A. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 1983, 15:25-35.